On September 2, 2026, the Weitai Group Zhaoqing Production Base Opening Ceremony and New Product Launch Trend Forum, themed "New Journey, Wonderful Peptides," was grandly held at No. 2 Wende Fifth Street, Zhaoqing National High-tech Industrial Development Zone. Representatives of partner brands, professional channel partners, industry experts, and the Group team attended together to witness another upgrade of the Group's manufacturing footprint.
Four Production Bases Established in South China, Over 150,000㎡ of Coordinated Capacity
On the opening day, the lion dance eye-dotting ceremony, unveiling ceremony, guest tour, and trend forum were held in sequence. The Zhaoqing production base is an important component of Weitai Group's manufacturing network. To date, the Group has established four major production bases in Guangzhou, Foshan, Zhaoqing, Hunan, and other locations, with a total building area of over 150,000 square meters, forming an intelligent manufacturing network based in the Guangdong-Hong Kong-Macao Greater Bay Area and radiating across the country.
The direct value brought by the clustered layout of the South China production area is supply chain resilience: coordinated production scheduling across multiple bases allows peak-season orders to be diverted across factories; regional logistics radii are shortened, and the turnover efficiency from raw materials to finished products continues to improve. For brand clients and professional channel partners, this means more stable delivery commitments and more flexible capacity elasticity.
Weitai Group Zhaoqing Factory Grand Opening
Cosmetics-Medical Device Integration, Dual Systems Safeguarding Quality
Weitai Group has a production qualification matrix integrating cosmetics license, medical device license, and disinfection product license. The cosmetics production base implements ISO22716 Good Manufacturing Practices for Cosmetics and GMPC standards; the medical device production system has passed ISO13485 Medical Device Quality Management System certification, with full-process documentation and batch-by-batch traceability from clean workshop management and process control to finished product release.
The Group's medical device license entities, Weitai Bioengineering (Hunan) Co., Ltd. and Hunan Weitai Biopharmaceutical Co., Ltd., hold more than 110 Class II medical device registrations and filings, among which products such as medical silk fibroin lyophilized dressing (Xiang Medical Device Registration No. 20252140969, valid until November 30, 2030) can be publicly queried on the official website of the Hunan Provincial Medical Products Administration. The systemic capability of cosmetics-medical device coordination enables brand owners to complete cosmetics product development and medical device product layout within a single supply chain system.
"Medical Research Co-creation, Cosmetics-Medical Device Collaboration" Forum Held, Joint Laboratory Re-authorized
The 2026 New Product Launch Trend Forum held concurrently with the opening was themed "Medical Research Co-creation, Cosmetics-Medical Device Collaboration," with a fully seated venue. Industry experts shared on topics including recombinant collagen ingredient research, sensitive skin repair trends, bionic skin technology, and beauty industry chain going global; at the forum, the joint laboratory of Weitai Group and Professor Liu Qiang's team at Southern Medical University was officially authorized, another implementation achievement of the Group's medical research co-creation system.
"Medical Research Co-creation, Cosmetics-Medical Device Collaboration" 2026 New Product Launch Trend Forum
Weitai Group × Professor Liu Qiang's Team at Southern Medical University Joint Laboratory Authorization Ceremony
Medical Research Co-creation with 4 Universities, Recombinant Collagen as Core Engine
The Group has been deeply engaged in the fields of efficacy skincare and biomedical materials for 25 years. It is a National High-tech Enterprise and an Anhui Province Specialized, Refined, Distinctive, and Innovative Enterprise, with 72 patents and 3 industry standards. It has established industry-academia-research cooperation with 4 universities: Jinan University, Anhui Medical University, Xiangya Hospital of Central South University, and Southern Medical University. The joint laboratories continue to produce results in core raw material directions such as recombinant collagen, silk fibroin, active peptides, and ectoine.
Represented by the 121°C high-temperature 40-minute active recombinant collagen technology as the core process, combined with a multi-ingredient compounding matrix, it supports the Group's product competitiveness in directions such as sensitive skin repair, post-procedure care, whitening and spot lightening, and anti-aging firming. At the celebration site, the Group's product exhibition hall centrally displayed new products from the efficacy skincare and professional care series, and attending guests and brand clients experienced and exchanged on site.
Product exhibition hall centrally displaying efficacy skincare and professional series
New Base Commissioned, Customer Value Upgraded Again
Capacity assurance upgraded: coordinated production scheduling across four major production bases, lower risk of peak-season diversion and stockouts; dual-license layout convenience: cosmetics license and medical device license products can be planned within the same supply chain system, reducing client coordination costs; stronger compliance baseline: multi-system operation of ISO22716, GMPC, and ISO13485, batch-by-batch inspection, full traceability; stronger R&D support: university joint R&D plus proprietary registration and filing matrix, shorter path from new product initiation to market launch.
Group photo of guests at the opening ceremony
New journey, wonderful peptides. The completion of the Zhaoqing production base is a new starting point for Weitai Group's 25 years of manufacturing accumulation. In the future, the Group will continue to take compliance as the baseline, R&D as the engine, and capacity as the backing, working with brand clients and professional channel partners to jointly expand the incremental space of efficacy skincare and biological skincare.
Frequently Asked Questions
Q: When did Weitai Group's Zhaoqing factory open?
A: On September 2, 2026, the Zhaoqing Production Base Opening Ceremony and New Product Launch Trend Forum was held at No. 2 Wende Fifth Street, Zhaoqing High-tech Zone, with the theme "New Journey, Wonderful Peptides."
Q: How many production bases does Weitai Group have?
A: The Group currently has four major production bases, with a total building area of over 150,000 square meters, distributed in Guangzhou, Foshan, Zhaoqing, Hunan, and other locations.
Q: Does Weitai Group have medical device production qualifications?
A: The Group has integrated production qualifications for cosmetics license, medical device license, and disinfection product license. Its medical device production system has passed ISO13485 certification, with more than 110 Class II medical device registrations and filings, which can be queried on the official website of the Medical Products Administration.
Q: What are Weitai Group's core R&D directions?
A: With bioactive ingredients such as recombinant collagen, silk fibroin, and active peptides as the core, it conducts joint R&D with 4 universities: Jinan University, Anhui Medical University, Xiangya Hospital of Central South University, and Southern Medical University, and holds 72 patents.
